These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32795875)

  • 1. Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
    Retèl VP; Byng D; Linn SC; Jóźwiak K; Koffijberg H; Rutgers EJ; Cardoso F; Piccart MJ; Poncet C; Van't Veer LJ; van Harten WH
    Eur J Cancer; 2020 Sep; 137():193-203. PubMed ID: 32795875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
    Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
    Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
    Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
    Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer.
    Bonastre J; Marguet S; Lueza B; Michiels S; Delaloge S; Saghatchian M
    J Clin Oncol; 2014 Nov; 32(31):3513-9. PubMed ID: 25287824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
    Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
    Wang SY; Chen T; Dang W; Mougalian SS; Evans SB; Gross CP
    J Natl Compr Canc Netw; 2019 Jan; 17(1):39-46. PubMed ID: 30659128
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.
    Kondo M; Hoshi SL; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2012 Jun; 133(2):759-68. PubMed ID: 22315134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
    Retèl VP; Joore MA; Drukker CA; Bueno-de-Mesquita JM; Knauer M; van Tinteren H; Linn SC; van Harten WH
    Eur J Cancer; 2013 Dec; 49(18):3773-9. PubMed ID: 23992641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
    Millar JA; Millward MJ
    Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
    Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
    Leung W; Kvizhinadze G; Nair N; Blakely T
    PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Marguet S; Mazouni C; Ramaekers BL; Dunant A; Kates R; Jacobs VR; Joore MA; Harbeck N; Bonastre J
    Eur J Cancer; 2016 Aug; 63():168-79. PubMed ID: 27322916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of MammaPrint
    Luyendijk M; Jager A; Buijs SM; Siesling S; Groot CAU; Blommestein HM
    Pharmacoeconomics; 2023 Aug; 41(8):981-997. PubMed ID: 37245167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
    Blank PR; Filipits M; Dubsky P; Gutzwiller F; Lux MP; Brase JC; Weber KE; Rudas M; Greil R; Loibl S; Szucs TD; Kronenwett R; Schwenkglenks M; Gnant M
    Pharmacoeconomics; 2015 Feb; 33(2):179-90. PubMed ID: 25404424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
    Kip M; Monteban H; Steuten L
    J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.